Boehringer Ingelheim Pharmaceuticals, Inc.: Drug Recall
Recall #D-0468-2023 · 03/09/2023
Class II: Risk
Recall Details
- Recall Number
- D-0468-2023
- Classification
- Class II
- Product Type
- Drug
- Recalling Firm
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Status
- Terminated
- Date Initiated
- 03/09/2023
- Location
- Ridgefield, CT, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 69,375 bottles
Reason for Recall
Labeling: Label Mix-up
Product Description
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Distribution Pattern
Product was distributed nationwide within the United States and PR
Other Recalls by Boehringer Ingelheim Pharmaceuticals, Inc.
- Class II: Risk 05/04/2021
View all recalls by Boehringer Ingelheim Pharmaceuticals, Inc. →
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.